Home / Market News / $MNOV

$MNOV news and market catalysts

The 6 most recent market catalysts affecting $MNOV, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

6 catalysts 1 high impact 2 bullish 1 bearish Biotechnology
Oct 12, 2026 Corporate Catalyst Bullish Impact 65
MediciNova Provides Update On Recent Topline Results Of Its Phase 2 Clinical Trial Evaluating MN-001 For Treatment Of Nonalcoholic Fatty Liver Disease And Hypertriglyceridemia Associated With Type 2 Diabetes Mellitus; At End Of The 24-Week Period, Serum Triglycerides, Liver Fat, And Body Weight Were Also Reduced In The MN-001 Group Compared With Placebo, Although These Differences Did Not Reach Statistical Significance
MediciNova (MNOV) released topline results from its Phase 2 clinical trial for MN-001 in nonalcoholic fatty liver disease (NAFLD) and hypertriglyceridemia. While the trial did not …
Sep 28, 2026 Corporate Catalyst Bearish Impact 85
MediciNova shares are trading lower after the company announced the topline results from MN-001-NATG-202, a Phase 2 clinical trial evaluating MN-001 for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease associated with type 2 diabetes mellitus.
The negative topline results from the MN-001-NATG-202 trial are a major blow to MediciNova, as MN-001 is a significant asset in their development pipeline. This failure casts doubt…
Sep 24, 2026 Corporate Catalyst Neutral Impact 65
MediciNova Completes Last Patient, Last Visit In The Double-Blind Portion Of COMBAT-ALS Phase 2B/3 Clinical Trial Evaluating MN-166 For The Treatment Of Amyotrophic Lateral Sclerosis
MediciNova has completed the double-blind portion of its COMBAT-ALS Phase 2B/3 clinical trial for MN-166, an important operational step in drug development. This event is significa…
Sep 17, 2026 Corporate Catalyst Bullish Impact 75
MediciNova shares are trading higher after Roth Capital initiated coverage on the stock with a Buy rating and announced a $6 price target.
This headline indicates a strong positive catalyst for MediciNova. Analyst initiations, especially with a 'Buy' rating and a specific price target, often lead to increased investor…
Sep 17, 2026 Corporate Catalyst Neutral Impact 65
Roth Capital Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $6
Roth Capital's initiation of coverage on MediciNova with a 'Buy' rating and a $6 price target is a positive development for the company. Analyst coverage, especially with a positiv…
Jul 15, 2026 Corporate Catalyst Neutral Impact 75
MediciNova Enrolls 200 Patients In SEANOBI-ALS Study
The enrollment of 200 patients in the SEANOBI-ALS study is a crucial step for MediciNova, signaling that the trial is progressing as planned and nearing completion of its recruitme…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.